Tags: biotechpatientpharmaPolicy & Regulationpolicy-regulation
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | Katie Adams MedCity News Editor. Exeter, New Hampshire | ||
| 2 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | Andrew Caldwell - 6 months ago | |
| 3 | Natasha Lomas TechCrunch Journalist. Climber-in-training. Owns cats. Barcelona and London | ||
| 4 | Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts | STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 15 days ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 7 months ago | |
| 5 | Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois | STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 15 days ago It’s happy hour (for now) for Alnylam - 2 months ago | |
| 6 | Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. | ||
| 7 | Sophie Putka MedPage Today Enterprise, investigative writer. New York, USA | ||
| 8 | PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom | Theramex’s Eladynos recommended by NICE for post-menopausal bone disease - about 1 month ago | |
| 9 | Michael Nuñez VentureBeat Editorial Director at VentureBeat. San Francisco | Meshy-4 brings sci-fi level AI to 3D modeling and design - 29 days ago | |
| 10 | Emily Mullin Wired Staff writer at WIRED. Covers biotechnology. Fall 2021 fellow. Pittsburgh, Pennsylvania | The Uncertain Path Forward for Psychedelic Medicine - about 1 month ago |